氨磷汀对老年急性白血病化疗患者的疗效与安全性评价

Clinical efficacy and safety of amifostine on elderly patients with acute leukemia receiving chemotherapy

目的评价氨磷汀在老年急性白血病化疗患者中的临床疗效及安全性。方法 58例多次接受化疗和氨磷汀细胞保护治疗的急性白血病患者分为2组,老年组28例（年龄≥60岁）和对照组30例（年龄〈60岁）。2组于化疗前15～30 min静脉推注氨磷汀600 mg·m^-2,持续15 min,连续用4个周期,比较氨磷汀对2组患者恶心呕吐等化疗不良反应发生率及血压的影响。结果老年组与对照组患者恶心呕吐、皮疹、口干等不良反应发生率差异无统计学意义（P〉0.05）;老年组患者收缩压下降82例次（80.4%）,舒张压下降71例次（69.6%）;对照组收缩压下降106例次（80.3%）,舒张压下降83例次（62.9%）,2组患者收缩压与舒张压下降比例差异无统计学意义（P〉0.05）。结论在接受化疗的老年急性白血病患者中用氨磷汀是安全的,可减少老年患者化疗相关不良反应。

Objective To evaluate the clinical efficacy and safety of amifostine on elderly acute leukemia patients receiving chemotherapy.Methods Fifty- eight patients with acute leukemia treated with chemotherapy and amifostine were recruited in this study and then divided into two groups,28 cases in elderly group（ ≥ 60 years） and 30 cases in control group（〈 60 years）. All the patients were given amifostine 600mg·m^-2 through intravenous injection 15 to 30 minutes prior chemotherapy for 4 cycles. The data of the influence of amifostine on chemotherapy-induced adverse reactions as well as patients＇ blood pressure were compared in two groups. Results There was no statistical difference in incidence rates of chemotherapy- induced adverse reactions in two groups（ P〉0. 05）. After chemotherapy,there were 82（ 80. 4%） and102（ 80. 3%） cases showing decreasing systolic blood pressure in elderly group and control group, respectively, and 71（ 69. 6%） and 83（ 62. 9%） cases showing decreasing diastolic blood pressure（ P〉0. 05）. Conclusion The application of amifostine on elderly acute leukemia patients who has received chemotherapy is safe and could relieve chemotherapy- induced adverse reactions.